quinazolines has been researched along with Cystadenocarcinoma, Serous in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, B; Li, Y; Liu, Z; Shu, T; Wu, X | 1 |
| Azodi, M; Bellone, S; Bonazzoli, E; Bortolomai, I; Cocco, E; English, DP; Lopez, S; Nicoletti, R; Ratner, E; Roque, DM; Rutherford, TJ; Santin, AD; Schwab, CL; Schwartz, PE; Silasi, DA | 1 |
| Borger, DR; Byron, VF; DiGloria, CM; Foster, R; Groeneweg, JW; Growdon, WB; Hernandez, SF; Kim, M; Lopez, H; Rueda, BR; Scialabba, V; Tambouret, R; Zhang, L | 1 |
| Annunziata, CM; Calvo, K; Choyke, P; Kimm, D; Kohn, EC; Kotz, H; Minasian, L; Steinberg, SM; Walker, AJ; Wood, BJ; Yu, M | 1 |
| Harada, T; Itamochi, H; Kato, M; Kigawa, J; Kudoh, A; Naniwa, J; Nishimura, M; Nonaka, M; Oishi, T; Sato, S; Shimada, M; Terakawa, N | 1 |
| Espina, V; Godwin, AK; Hussain, MM; Kohn, EC; Kwitkowski, V; Liel, MS; Minasian, L; Posadas, EM; Steinberg, SM; Wood, BJ | 1 |
2 trial(s) available for quinazolines and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Cystadenocarcinoma, Serous; Drug Administration Schedule; ErbB Receptors; Female; Humans; Middle Aged; Ovarian Neoplasms; Piperidines; Protein Kinase Inhibitors; Quinazolines; Recurrence; Signal Transduction; Treatment Failure; Vascular Endothelial Growth Factor Receptor-2 | 2010 |
A phase II and pharmacodynamic study of gefitinib in patients with refractory or recurrent epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents; Carcinoma, Endometrioid; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; ErbB Receptors; Female; Gefitinib; Humans; Middle Aged; Mitogen-Activated Protein Kinase 1; Neoplasm Recurrence, Local; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Phosphorylation; Polymerase Chain Reaction; Prospective Studies; Proto-Oncogene Proteins c-akt; Quinazolines; Signal Transduction; Time Factors; Treatment Outcome | 2007 |
4 other study(ies) available for quinazolines and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
Down-regulation of HECTD3 by HER2 inhibition makes serous ovarian cancer cells sensitive to platinum treatment.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carboplatin; Cell Line, Tumor; Cystadenocarcinoma, Serous; Down-Regulation; Female; HEK293 Cells; Humans; Lapatinib; Mice; Mice, Nude; Middle Aged; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; STAT3 Transcription Factor; Ubiquitin-Protein Ligases | 2017 |
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo.
Topics: Adult; Afatinib; Aged; Aged, 80 and over; Animals; Apoptosis; Cell Cycle; Cell Proliferation; Cystadenocarcinoma, Serous; Endometrial Neoplasms; Female; Humans; Immunoenzyme Techniques; In Situ Hybridization, Fluorescence; In Vitro Techniques; Mice; Mice, SCID; Middle Aged; Phosphorylation; Quinazolines; Receptor, ErbB-2; Signal Transduction; Tumor Cells, Cultured; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Dual HER2 targeting impedes growth of HER2 gene-amplified uterine serous carcinoma xenografts.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cystadenocarcinoma, Serous; Disease Models, Animal; Female; Gene Amplification; Gene Expression; Humans; Lapatinib; Mice; Protein Kinase Inhibitors; Quinazolines; Receptor, ErbB-2; Signal Transduction; Trastuzumab; Tumor Burden; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2014 |
Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2.
Topics: Aged; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cystadenocarcinoma, Serous; Cytological Techniques; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Lapatinib; Mice; Mice, Inbred BALB C; Mice, Nude; Ovarian Neoplasms; Quinazolines; Receptor, ErbB-2; Signal Transduction; Xenograft Model Antitumor Assays | 2012 |